- Home
- MDXH vs CNTX Comparison
MDXH vs CNTX Comparison
Compare MDXH & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- CNTX
- Stock Information
- Founded
- MDXH 2003
- CNTX 2015
- Country
- MDXH Belgium
- CNTX United States
- Employees
- MDXH N/A
- CNTX N/A
- Industry
- MDXH
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- MDXH
- CNTX Health Care
- Exchange
- MDXH Nasdaq
- CNTX Nasdaq
- Market Cap
- MDXH 84.6M
- CNTX 78.0M
- IPO Year
- MDXH 2021
- CNTX 2021
- Fundamental
- Price
- MDXH $2.18
- CNTX $0.63
- Analyst Decision
- MDXH Buy
- CNTX Strong Buy
- Analyst Count
- MDXH 1
- CNTX 5
- Target Price
- MDXH $6.00
- CNTX $5.50
- AVG Volume (30 Days)
- MDXH 67.5K
- CNTX 330.3K
- Earning Date
- MDXH 08-20-2025
- CNTX 08-06-2025
- Dividend Yield
- MDXH N/A
- CNTX N/A
- EPS Growth
- MDXH N/A
- CNTX N/A
- EPS
- MDXH N/A
- CNTX N/A
- Revenue
- MDXH $94,507,000.00
- CNTX N/A
- Revenue This Year
- MDXH $23.51
- CNTX N/A
- Revenue Next Year
- MDXH $17.68
- CNTX N/A
- P/E Ratio
- MDXH N/A
- CNTX N/A
- Revenue Growth
- MDXH 25.46
- CNTX N/A
- 52 Week Low
- MDXH $1.35
- CNTX $0.49
- 52 Week High
- MDXH $3.50
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- MDXH 58.07
- CNTX 50.76
- Support Level
- MDXH $2.13
- CNTX $0.62
- Resistance Level
- MDXH $2.32
- CNTX $0.70
- Average True Range (ATR)
- MDXH 0.12
- CNTX 0.05
- MACD
- MDXH 0.01
- CNTX 0.01
- Stochastic Oscillator
- MDXH 76.19
- CNTX 56.44
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.